Wockhardt, the pharmaceutical and biotechnology major, posted robust results for the third quarter of FY2025-26, driven by strong domestic and international business performance.
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year. Revenue rose 22% to Rs.888 crore, compared to Rs.725 crore in Q3FY25, while EBITDA surged 72% to Rs.173 crore, from Rs.100 crore a year ago.
On financial performance, the company noted:
“Exceptional Items of Rs.107 crore for 9MFY26 includes the impact of US entity liquidation and the New Labour code.”
Wockhardt’s biotech operations achieved Rs.213 crore in Q3, reflecting a 96% growth versus Q4FY25 and 38% growth versus Q2FY26. The company said, “This robust achievement is fuelled by our Emerging Market biotech segment growing at >50% with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Thailand, Egypt, Algeria and LATAM.”
Domestic biotech operations continue to expand at a double-digit pace, the company added, noting that the upcoming launch of Insulin analogs represents a significant business opportunity, strengthening Wockhardt’s leadership in global diabetes care.
Business Highlights Across Markets
India Branded Business: Rs.146 crore, up 28%, driven by diabetic therapy, NCE (EMROK), and the new Regenerative Derma segment.
UK Region: Rs.343 crore, up 15%.
Emerging Markets: Rs.264 crore, up 48%, led by the Biotech Insulin segment, with strong traction in LATAM.
Irish Region: Rs.57 crore, up 23%.
New Products and Approvals
International Business: 9 filings and 17 launches.
Biosimilars: 11 filings and 11 approvals.
NCE: 2 filings and 1 approval.
Wockhardt’s integrated biotech infrastructure and strategic market expansions continue to underpin its growth strategy.
